Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Costco Wholesale
COSTConsumer StaplesGenerated Jul 5, 2026, 08:55 PM UTC
COST (Costco Wholesale) analytical snapshot. Revenue grew +6.8% YoY to $242.29B. 5-year revenue CAGR +9.7%; 10y CAGR +8.9%. Net margin at 2.60% (expanding ▲). Market cap $422.05B at $951.67 per share. Trailing P/E 67.21, P/S 1.74, P/B 12.59. EV/Operating income ≈ 50.50 (EV $409.72B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score -18 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$422.05B
443.48M shares
Price
$951.67
NMS
P/E (ttm)
67.21
Revenue (FY)
$242.29B
YoY +6.8%
Net margin
2.60%
▲ 0.20pp
Free cash flow
$6.75B
2.78% margin
Risk level
Moderate
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 40Improving
80% conf
Revenue grew +6.8% YoY to $242.29B. 5-year revenue CAGR +9.7%; 10y CAGR +8.9%. Net margin at 2.60% (expanding ▲).
- Revenue grew +6.8% YoY to $242.29B.
- 5-year revenue CAGR +9.7%; 10y CAGR +8.9%.
- Net margin at 2.60% (expanding ▲).
- Return on equity 26.64%, ROA 9.12%, ROIC 34.35%.
- Gross margin 0.00%, operating margin 3.35%.
- Free cash flow margin 2.78% ($6.75B).
- Net income up ▲ +7.7% YoY.
- Debt/equity 0.20, current ratio 1.07, net debt -$12.33B.
- Asset turnover 2.80 — capital efficiency.
Revenue (FY)
$242.29B
YoY +6.8%
Net margin
2.60%
▲ 0.20pp
ROE
26.64%
ROA 9.12%
ROIC
34.35%
EPS (diluted)
$14.16
FY2025
Free cash flow
$6.75B
2.78% margin
Debt / equity
0.20
Cash $18.95B
Current ratio
1.07
Equity $33.51B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $112.64B | — | 0.00 | 2.86 | 1.83 | — | 19.38 |
| 2017 | $116.20B | +3.2% | 0.00 | 3.12 | 2.05 | — | 19.68 |
| 2018 | $118.72B | +2.2% | 0.00 | 3.09 | 1.98 | — | 21.80 |
| 2019 | — | — | — | — | — | — | 0.00 |
| 2020 | $141.58B | — | 0.00 | 3.16 | 2.21 | $2.81B | 20.56 |
| 2021 | $152.70B | +7.9% | 0.00 | 3.10 | 2.40 | $3.36B | 20.01 |
| 2022 | $166.76B | +9.2% | 0.00 | 3.26 | 2.40 | $6.05B | 22.79 |
| 2023 | $195.93B | +17.5% | 0.00 | 3.42 | 2.56 | $5.37B | 24.26 |
| 2024 | $226.95B | +15.8% | 0.00 | 3.43 | 2.57 | $3.50B | 23.32 |
| 2025 | $242.29B | +6.8% | 0.00 | 3.35 | 2.60 | $6.75B | 26.64 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Feb 16, 2025 | $63.72B | — | — | 5.63% |
| May 11, 2025 | $189.08B | — | +196.7% | 2.90% |
| May 11, 2025 | $63.20B | — | -66.6% | 8.68% |
| Nov 23, 2025 | $67.31B | — | +6.5% | 2.97% |
| Feb 15, 2026 | $136.90B | — | +103.4% | 2.95% |
| Feb 15, 2026 | $69.60B | — | -49.2% | 5.80% |
Revenue (annual, SEC 10-K)
2016: 112,640
2017: 116,199
2018: 118,719
2019: 0
2020: 141,576
2021: 152,703
2022: 166,761
2023: 195,929
2024: 226,954
2025: 242,290
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 0
2017: 0
2018: 0
2019: 0
2020: 2,805
2021: 3,358
2022: 6,051
2023: 5,370
2024: 3,501
2025: 6,745
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score -10Stable
80% conf
Latest annual report (10-K) filed Oct 8, 2025. Latest quarterly report (10-Q) filed Jun 3, 2026. 13 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Oct 8, 2025.
- Latest quarterly report (10-Q) filed Jun 3, 2026.
- 13 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 3 sell transactions — net selling $2.3M.
- ~10,000+ recent 13F-HR filings reference Costco Wholesale; broad institutional reporting.
- Recent filers include Carroll Investors, Inc, Game Plan Financial Advisors, LLC, Silver Grove Financial Group, Inc..
- 20 recent 13G passive institutional ownership notices.
Latest 10-K
Oct 8, 2025
Annual report
Latest 10-Q
Jun 3, 2026
8-K (recent)
13
Insider net
-$2.3M
0B/3S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| Carroll Investors, Inc | 13F-HR | Apr 28, 2022 |
| Game Plan Financial Advisors, LLC | 13F-HR | Apr 12, 2024 |
| Silver Grove Financial Group, Inc. | 13F-HR | Feb 13, 2026 |
| Foresters Asset Management Inc. | 13F-HR | Nov 14, 2016 |
| RG CAPITAL MANAGEMENT LP | 13F-HR | Feb 13, 2003 |
Recent insider Form 4 activity
| Insider | Date | Net | Buys/Sells |
|---|---|---|---|
| DENMAN KENNETH D | Jun 25, 2026 | -$847.3K | 0/1 |
| Frates Caton | Apr 1, 2026 | -$695.1K | 0/1 |
| Adamo Claudine | Mar 11, 2026 | -$732.2K | 0/1 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 28, 2026 | 8-K | 8-K |
| Apr 15, 2026 | 8-K | 8-K |
| Mar 5, 2026 | 8-K | 8-K |
| Jan 21, 2026 | 8-K | 8-K |
| Dec 11, 2025 | 8-K | 8-K |
| Oct 20, 2025 | 8-K | 8-K |
| Oct 15, 2025 | 8-K | 8-K |
| Sep 25, 2025 | 8-K | 8-K |
Insider Form 4 sentiment (transactions)
Buys: 0
Sells: 3
Buys
Sells
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -35Deteriorating
68% conf
2 risk signal(s), 1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Material weakness in internal controls: The term "material weakness" appears in 25 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Operating cash flow exceeds net income: OCF is 1.76x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- NEW: Restructuring: Restructuring appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 5 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Restatement of financial statements, Impairment charge, Restructuring.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$242.29B
+6.8% YoY
Gross profit
$16.46B
— YoY
Operating income
$8.11B
+4.1% YoY
Net income
$6.29B
+7.7% YoY
Operating cash flow
$11.07B
+49.7% YoY
Capex
$4.32B
+11.1% YoY
Total assets
$68.99B
+7.5% YoY
Total liabilities
$46.21B
+5.2% YoY
Filing quality score
80/100
5 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $226.95B | $242.29B | $15.34B | +6.8% |
| Gross profit | — | $16.46B | — | — |
| Operating income | $7.79B | $8.11B | $321.0M | +4.1% |
| Net income | $5.84B | $6.29B | $448.0M | +7.7% |
| Operating cash flow | $7.39B | $11.07B | $3.68B | +49.7% |
| Capex | $3.89B | $4.32B | $432.0M | +11.1% |
| Total assets | $64.17B | $68.99B | $4.83B | +7.5% |
| Total liabilities | $43.94B | $46.21B | $2.27B | +5.2% |
| Long-term debt | $6.85B | $7.66B | $805.0M | +11.7% |
| Cash & equivalents | $13.70B | $9.91B | $-3.79B | -27.7% |
| Stockholders equity | $25.06B | $23.62B | $-1.44B | -5.7% |
| Inventory | $16.65B | $18.65B | $2.00B | +12.0% |
| SG&A expense | $19.78B | $21.59B | $1.81B | +9.2% |
| Interest expense | $158.0M | $160.0M | $2.0M | +1.3% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax, NumberOfReportableSegments, RepaymentsOfDebt |
| Removed | AccruedInsuranceCurrentAndNoncurrent, AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, BuildingsAndImprovementsGross, ConstructionInProgressGross, CreditAndDebitCardReceivablesAtCarryingValue, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DebtInstrumentRedemptionPricePercentage, DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 25 | 2 | Ongoing |
| Restatement of financial statements | high | 1 | 0 | NEW |
| Impairment charge | medium | 18 | 0 | NEW |
| Restructuring | medium | 13 | 0 | NEW |
| Off-balance sheet arrangements | medium | 24 | 2 | Ongoing |
Filing signal breakdown
Red flags: 2
Positive: 1
Watch: 2
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $422.05B at $951.67 per share.
- ProPrice & TechnicalsPrice $951.67 — downtrend (below 200-DMA); 1-month momentum negative.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -18
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Costco Wholesale is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewRevenue grew **+6.8%** YoY to $242.29B..
Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow COST stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST● you | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |